Related Experiment Video

Updated: May 21, 2026

Cell Death Associated with Abnormal Mitosis Observed by Confocal Imaging in Live Cancer Cells
15:53

Cell Death Associated with Abnormal Mitosis Observed by Confocal Imaging in Live Cancer Cells

Published on: August 21, 2013

PPARs: Interference with Warburg' Effect and Clinical Anticancer Trials

Joseph Vamecq1, Jean-Marie Colet, Jean Jacques Vanden Eynde

  • 1Inserm, HMNO, CBP, CHRU Lille, 59037 Lille, France.

PPAR Research
|June 2, 2012
PubMed

Insights

Cancer cells exhibit altered metabolism, including aerobic glycolysis driven by hypoxia-induced factor (HIF-1). PPAR ligands show promise in targeting tumoral metabolism for cancer treatment, potentially combined with other agents.

Area of Science:

  • Oncology
  • Cancer Metabolism
  • Molecular Signaling

Background:

  • The Warburg effect (aerobic glycolysis) and general cancer cell metabolic phenotypes are reviewed.
  • Hypoxia-induced factor (HIF-1) plays a central role in aerobic glycolysis expression.
  • Cancer metabolism is influenced by signaling pathways like ras, myc, p53, and Akt.

Purpose of the Study:

  • To provide an integrated view of tumoral metabolism.
  • To explore emerging cancer treatment strategies.
  • To examine the role of PPAR ligands in cancer therapy.

Main Methods:

  • Review of metabolic and cell signaling pathways in cancer.
  • Analysis of signaling aberrances and their therapeutic implications.
  • Examination of PPAR ligand mechanisms and clinical trial data.

Main Results:

  • Cancer metabolic phenotype involves aerobic glycolysis and altered signaling routes.
  • Aberrant signaling in cancer cells presents therapeutic intervention opportunities.
  • PPAR ligands demonstrate potential to interfere with tumoral metabolism and exhibit anticancer activity.

Conclusions:

  • Emerging cancer treatment strategies target tumoral metabolism.
  • PPAR ligands offer a direct mechanism to impact cancer metabolism.
  • Combining PPAR ligands with other anticancer agents may be crucial for effective treatment.

More Related Videos

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...